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Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease with involvement of both B cells and cytotoxic
T lymphocytes and several cytokines aberrations. Standard therapy for SLE has its limitations. Tacrolimus, a novel calcineurin
inhibitor with potent immunosuppressive eﬀects, has been shown in the recent years to be eﬀective in SLE therapy. This paper
serves to collate the experimental and clinical data on the eﬃcacy of tacrolimus in the treatment of SLE and lupus nephritis.
Tacrolimus as a key component of multitarget therapy in SLE is also discussed. The immunocytokine modulatory eﬀects of
tacrolimus are also reviewed with reference to SLE. It can be concluded that tacrolimus has an established role in the management
of SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a complex systemic
autoimmune disease with multiorgan involvement charac-
terized by autoantibody formation and immune complex
deposition. The pathogenesis of SLE is being unravelled
and involves a complex interplay of environmental triggers,
hormonal factors, susceptibility genes including genes that
control apoptosis rates, antigen/immune complex clearance,
lymphoid signaling, and genes that inﬂuence inﬂammatory
responses. Examples include lpr gene (Fas mutations) in
MRL mice; Clq gene polymorphism; mannose binding lectin
gene polymorphism; and IL-10 gene polymorphism [1].
Both B cells and cytotoxic T lymphocytes are involved
in the pathogenesis of SLE. The cytokine proﬁle of SLE has
been extensively studied. Current theory proposes an over-
expression of certain TH2 cytokines that suppress the TH1
response in lupus T-cells. Examples include studies in lupus-
prone F1 mice showing higher IFN-γ and IL-4 levels and
lower active TGF-β levels; and in patients with SLE, serum
IL-10 levels were higher than in controls and correlated with
disease activity [2, 3].
The standard therapy for SLE includes steroids, anti-
malarias, azathioprine (AZA), and cytotoxic therapy with
cyclophosphamide (CYC). Mycophenolate mofetil (MMF)
has been shown to be useful for lupus nephritis and also
recently rituximab, anti-B cell therapy has been shown to
be eﬃcacious for refractory cases. In this paper, however,
I would like to focus on tacrolimus (FK506, Prograf), a
relativelynewcalcineurininhibitorthathasbeenincreasingly
used in transplant medicine. Tacrolimus is a macrolide
compound isolated from Streptomyces tsukubaensis,as o i l
fungus found in Northern Japan. It was ﬁrst recognized
for its immunosuppressive properties and used extensively
in transplantation in the recent years. The objective of this
paper is to summarize the reported literature concerning the
clinical eﬃcacy of tacrolimus in the management of SLE and
the cytokine modulating eﬀects of tacrolimus.
1.1. Tacrolimus in Experimental SLE Models. There were
two studies involving MRL/lpr and B/W F1 mice, where
tacrolimus was administered to the mice with spontaneous
lupus nephritis [4]. The drug was able to reduce proteinuria
andprolongthelifespanofthelupusmiceandalsoprevented
the progression of the nephropathy. Histopathological study
showed that tacrolimus signiﬁcantly inhibited glomerular
hypercellularity and crescent formation. The elevated serum
anti-ds DNA was also suppressed by tacrolimus [5].2 Journal of Biomedicine and Biotechnology
1.2. Tacrolimus Therapy for SLE without Renal Involvement.
Duddridge was the ﬁrst to report the eﬃcacy of tacrolimus
in the treatment of 2 SLE patients with severe cutaneous
vasculitis, where cyclophosphamide and cyclosporin had
failed [6]. Subsequently, there were some reports of topical
tacrolimus being eﬀective for malar rash, chronic discoid
lupus, and treatment-resistant cutaneous lupus erythemato-
sus[7–9].ArecentreportfromJapanalsosuccessfullytreated
10 SLE patients without renal involvement with tacrolimus
[10]. The mean SLE Disease Activity Index (SLEDAI)
signiﬁcantly decreased after 1 year with a reduction of mean
doseofprednisolone.Theauthorhasalsoreported2patients
with SLE with antiphospholipid syndrome who were treated
with tacrolimus and had improvement in the manifestations
of cutaneous vasculitis and arthritis [11].
1.3. Eﬃcacy of Tacrolimus in SLE with Renal Involvement
(Lupus Nephritis). The eﬃcacy of tacrolimus in SLE patients
with lupus nephritis was ﬁrst reported in 4 pediatric patients
who had persistent disease activity despite conventional
immunosuppressive therapy including AZA, MMF, or CYC
[12]. They had marked improvement in disease indices
during treatment with FK506.
The author was ﬁrst to report the therapeutic success
of tacrolimus in 6 adult SLE patients with relapsed lupus
nephritis [11]. All 6 patients had reduction in proteinuria,
having failed conventional immunosuppressive regimes.
Subsequent to these, several reports emerged regarding
the usage of tacrolimus in lupus nephritis. An open-labeled
pilot study using FK506 as an induction therapy for diﬀuse
proliferative lupus nephritis in 9 patients reported by Mok et
al. from Hong Kong showed complete response in 67% and
22% had partial response [13]. This was further conﬁrmed
by 2 reports from Zhang et al. where FK506 was found to be
comparable to intravenous CYC in the induction therapy of
class IV lupus nephritis [14].
EﬀectivenessoftacrolimusformembranousclassVlupus
nephritis was also conﬁrmed in case reports and other case
series from Japan and Hong Kong [15–17]. As compared
with conventional cytotoxic treatment, tacrolimus resulted
in a faster resolution of proteinuria, and a lower risk of lupus
ﬂare within 1 year.
Recent reports from Japan also showed tacrolimus at
3mg/daytobeeﬀective and safe for maintenance treatment
up to one-year follow-up in lupus nephritis [18]. Another
double-blind, placebo-controlled study in 63 patients by
Nobuyuki et al. also showed that the addition of tacrolimus
at 3mg/day to glucocorticoid therapy resulted in signiﬁcant
improvement in lupus nephritis compared with placebo, up
to 28 weeks [19].Thiswasevidentbyreductioninthedisease
activity index, reduction in urinary protein excretion, and
increase in complement C3 level.
A novel immunotherapeutic approach has been recently
proposedandstudiedbyBaoetal.forthetreatmentofmixed
class V + IV lupus nephritis that is resistant to conventional
treatment [20]. Remission rates of this subtype of lupus
nephritis are low with only 21% with CTX therapy and
20% with MMF. A six-month study using tacrolimus as
induction therapy for this mixed class V + IV lupus nephritis
showed a response rate of 21.1% [21]. The new approach
of multitarget therapy using a combination of prednisolone,
MMF, and tacrolimus showed a signiﬁcantly much higher
complete remission at both 6 and 9 months (50% and 65%,
resp.) than with IV CYC (5% and 15%, resp.). In addition,
40% of patients had partial remission at 6 and 9 months
follow-up. Adverse events were also less frequent in the
multitarget therapy group.
1.4. Cytokine Modulating Eﬀects of Tacrolimus in SLE. The
pathogenesis of SLE is complex and involves the FC-
receptors system, complements, autoreactive T cells and
increased B cell activation, signal pathway alterations, with
expansion, hyperreactivity, and production of autoantibod-
ies. A consequence of ongoing T cell stimulation is release of
cytokines, and elevation of certain cytokines in SLE has been
well recognized, especially during periods of clinical activity.
The“lupusstorm”ofhyperpyrexiaandvascularcollapseseen
more in the presteroid era of SLE might also have had a
component of a cytokine release syndrome [22].
Interferon-α (IFN-α) was the ﬁrst cytokine found to
be elevated in SLE and increased levels correlated with
disease activity. High levels of tumour necrosis factor alpha
(TNF-α) have also been identiﬁed in some patients with
active SLE and positively correlate with levels of circulating
autoantibodies. Serum IL-6 and IL-10 are also increased in
SLE patients [23].
In SLE, it appears that both the TH1a n dT H2 responses
are in operation. A TH1 environment favours the production
of autoimmunity that is characterized by T cell mecha-
nisms, while autoimmunity involving antibody formation is
fostered by a TH2 environment. TH1 cells characteristically
produce IL-2, IFN-γ, IL-12, and TNF-α, while TH2c e l l s
secrete IL-4, IL-5, IL-6, IL-10, and IL-13.
Tacrolimus binds to FK-binding proteins (FKBPs) in the
cytoplasm, and the complex associates with the calcium-
dependent calcineurin/calmodulin complexes to impede
calcium-dependent signal transduction in lymphocytes [24].
This causes the transcription factors that promote cytokine
gene activation to be reduced.
Intermsofthecytokinemodulatingeﬀectsoftacrolimus,
it potently inhibits T cell activation-induced TNF-α and IL-
1β production in vitro by human peripheral blood mononu-
clear cells (PBMCs) [25]. Tacrolimus was also found to be
more potent than dexamethasone and cyclosporin A in that
regards. The cytokine suppressive eﬀects of tacrolimus have
been studied in various autoimmune conditions. Both TH1
(IL-2, IFN-γ)a n dT H2 cytokines (IL-4, IL-5) were found to
be suppressed by tacrolimus in atopic dermatitis [26]. In the
rat adjuvant-induced arthritis model, FK506 was found to be
more eﬀective than methotrexate in reducing elevated levels
of inﬂammatory cytokines, TNF-α,I L - 1 β, and IL-6 [27].
The suppression of IL-6 production and IgM production by
FK506 was also conﬁrmed in human PBMC [28]. This is
important in SLE therapy as IL-6 overexpression induces B
cell diﬀerentiation and increases production of autoantibod-
ies.Inthemyastheniagravismodel,wherePBMCsofpatients
were cultured for cytokine proﬁle and studied, the culture
study showed reduced IL-12, IL-17, IFN-γ,G M - C S F ,T N F - α,Journal of Biomedicine and Biotechnology 3
and MIP-1β in patients who received tacrolimus [29]. This
suggests that tacrolimus inhibits T cells and macrophages
and enhances type 1 regulatory T cells. A recent study
also conﬁrmed that treatment with tacrolimus inhibited the
expression of TH1cytokinemRNAinlupus-pronemice[30].
In addition, tacrolimus has been shown to inhibit
IL-10 production [31]. This is important as IL-10 plays
an important role in the pathogenesis of SLE [32]. The
deleterious eﬀects of IL-10 include stimulation of terminal
Bc e l ld i ﬀerentiation, activation induced cell death, and a
suppressive eﬀect on T cell. Elevated levels of IL-10 are seen
in SLE patients and correlated with SLE activity.
In terms of aﬀecting the humoral immunity response,
tacrolimus does not target B cells directly but works
indirectly by interfering with T cell help [33]. Tacrolimus
decreased the expression of the costimulating ligands
(CD154 and CD278), reducing the ability of T cells to
activate B cells. Tacrolimus also attenuated B cell stimulatory
cytokine mRNA levels in T cells, thereby abrogating B cell
signals necessary for activation and class-switching. Hence,
tacrolimus is able to inhibit T-cell-dependent immunoglob-
ulin production.
The ability of tacrolimus to aﬀe c tTc e l l si si m p o r -
tant in the immunotherapeutic strategy of SLE treatment.
Cytotoxic T lymphocytes is an important eﬀector pathway
in the pathogenesis of SLE. CD8+ T lymphocytes are
activated by SLE dendritic cells into eﬀector-type cytotoxic
T lymphocytes, and an increased proportion of cytotoxic T
l y m p h o c y t e sc o r r e l a t e dw i t hS L E D A Is c o r e s[ 34]. A recent
study found predominance of CD8+ T lymphocytes among
periglomerular-inﬁltrating cells in the renal biopsy speci-
mens of patients with class III/IV lupus nephritis [35]. Using
immunochemistry studies, renal CD8+ T cell inﬁltration
correlated with the renal activity index and high serum
creatinine levels. There were also correlations with cellular
crescents and Bowman’s capsule rupture, and association
with a poor response after conventional induction therapy.
This understanding may explain why the multitarget
therapy for the treatment of class V + IV lupus nephritis
was highly eﬀective with 90% achieving complete and partial
remission compared with 45% with IV CYC therapy. The
eﬀect of tacrolimus on T cells may be a critical component
of the observed beneﬁts in the study by Bao et al. [20] as the
severe focal and segmental forms of lupus nephritis have a
dominant T cell-dependent pathogenesis [36]. MMF, besides
suppressing lymphocyte proliferation and decreasing anti-
bodies formation, can suppress IL-2 production additionally
when given with tacrolimus [37]. Hence, multitarget therapy
using a combination of MMF, tacrolimus, and steroids,
previously shown to be an eﬀectivetreatmentforearlymixed
cellular and humoral renal allograft rejections in the ﬁeld of
organ transplantation, can now be applied to the therapy of
severe or resistant SLE, particularly lupus nephritis.
2. Conclusion
Having reviewed the experimental and clinical evidence
availabletodateontheeﬃcacyoftacrolimusinthetreatment
ofSLE,itcanbeconcludedthattacrolimushasanestablished
role in SLE management. Immunocytokine studies support
the clinical eﬃcacy of tacrolimus through direct T cell
suppression,inhibitingBcellactivityindirectlybyinterfering
with T helper signals and cytokine suppression including
TH1 cytokines, IL-2, IL-6, and IL-10.
Based on current available evidence, I would recommend
the usage of tacrolimus in SLE management as follows:
(1) as a steroid sparing agent;
(2) eﬀective in SLE without renal involvement;
(3) eﬀective in SLE with renal involvement;
(a) in class IV lupus nephritis,
(b) in class V lupus nephritis,
(c) in class V + IV lupus nephritis (as multitarget
therapy),
(4) as an induction therapy, maintenance therapy and
also in relapsed cases as a disease remitting agent.
Theuseofmultitargettherapyneedstobefurtherstudied
and even extrapolated to the management of severe SLE




[1] C. S. Lau, “Who’s afraid of the big bad wolf? Fifth Tay Chong
Hai lecture of the national arthritis foundation of Singapore,”
APLAR Journal of Rheumatology, vol. 7, no. 1, pp. 83–89, 2004.
[2] D. A. De Albuquerque, F. M. Ebling, D. W. Lienesch, R. R.
Singh, and B. H. Hahn, “Analyses of serum levels of type
1, type 2 and type 3 cytokines reveal multiple abnormalities
in lupus-prone (NZB × NZW) F1 mice,” APLAR Journal of
Rheumatology, vol. 7, no. 1, pp. 3–10, 2004.
[3] G. Grondal, I. Gunnarsson, J. Ronnelid, S. Rogberg, L.
Klareskog, and I. Lundberg, “Cytokine production, serum
levels and disease activity in systemic lupus erythematosus,”
Clinical and Experimental Rheumatology, vol. 18, no. 5, pp.
565–570, 2000.
[4] K.Takabayashi,T.Koike,K.Kurasawa,etal.,“EﬀectofFK-506,
a novel immunosuppressive drug on murine systemic lupus
erythematosus,” Clinical Immunology and Immunopathology,
vol. 51, no. 1, pp. 110–117, 1989.
[5] C. Entani, Y. Izumino, H. Iida, et al., “Eﬀect of a novel
immunosuppressant, FK506, on spontaneous lupus nephritis
in MRL/MpJ-lpr/lpr mice,” Nephron, vol. 64, no. 3, pp. 471–
475, 1993.
[6] M. Duddridge and R. J. Powell, “Treatment of severe and dif-
ﬁcult cases of systemic lupus erythematosus with tacrolimus:
a report of three cases,” Annals of the Rheumatic Diseases, vol.
56, no. 11, pp. 690–692, 1997.
[ 7 ]S .L .W a l k e r ,B .K i r b y ,a n dR .J .G .C h a l m e r s ,“ T h ee ﬀect of
topical tacrolimus on severe recalcitrant chronic discoid lupus
erythematosus,” British Journal of Dermatology, vol. 147, no.2,
pp. 405–406, 2002.
[8] T. Kanekura, N. Yoshii, K. Terasaki, H. Miyoshi, and T.
Kanzaki, “Eﬃcacy of topical tacrolimus for treating the malar
rash of systemic lupus erythematosus,” British Journal of
Dermatology, vol. 148, no. 2, pp. 353–356, 2003.4 Journal of Biomedicine and Biotechnology
[ 9 ] V .M a d a n ,P .J .A u g u s t ,a n dR .J .C h a l m e r s ,“ E ﬃcacy of topical
tacolimus 0.3% in clobetasol propionate 0.05% ointment in
therapy-resistant cutaneous lupus erythematosus: a cohort
study,” Clinical and Experimental Dermatology,v o l .3 5 ,n o .1 ,
pp. 27–30, 2010.
[10] K. Yoshie, T. Nahoko, K. Kaichi, et al., “Tacrolimus therapy
for systemic lupus erythematosus without renal involvement:
a preliminary retrospective study,” Modern Rheumatology, vol.
19, no. 6, pp. 329–333, 2009.
[11] K. H. Yoon, “Successful usage of tacrolimus (FK506) in
resistant/relapsed rheumatic diseases,” APLAR Journal of
Rheumatology, vol. 7, no. 1, pp. 44–48, 2004.
[12] C. L. Suzanne, K. Yukiko, L. Kenneth, et al., “Treatment of
pediatric patients with severe systemic lupus erythematosus
with tacrolimus,” Annals of Rheumatic Diseases, supplement,
pp. 48–49, 2003.
[ 1 3 ]C .C .M o k ,K .H .T o n g ,C .H .T o ,Y .P .S i u ,a n dT .C .
Au, “Tacrolimus for induction therapy of diﬀuse proliferative
lupus nephritis: an open-labeled pilot study,” Kidney Interna-
tional, vol. 68, no. 2, pp. 813–817, 2005.
[ 1 4 ]H .T .Z h a n g ,W .X .H u ,H .L .X i e ,e ta l . ,“ T a c r o l i m u sv e r s u s
intravenous cyclophosphamide in the induction therapy of
diﬀuse proliferative lupus nephritis,” Nephrology Dialysis
Transplantation, vol. 15, pp. 501–507, 2006.
[15] M. Maruyama, Y. Yamasaki, K. Sada, et al., “Good response of
membranous lupus nephritis to tacrolimus,” Clinical Nephrol-
ogy, vol. 65, no. 4, pp. 276–279, 2006.
[16] C.-C. Szeto, B. C.-H. Kwan, F. M.-M. Lai, et al., “Tacrolimus
for the treatment of systemic lupus erythematosus with pure
class V nephritis,” Rheumatology, vol. 47, no. 11, pp. 1678–
1681, 2008.
[17] K. C. Tse, M. F. Lam, S. C. W. Tang, C. S. O. Tang, and T. M.
Chan, “A pilot study on tacrolimus treatment in membranous
or quiescent lupus nephritis with proteinuria resistant to
angiotensin inhibition or blockade,” Lupus,v o l .1 6 ,n o .1 ,p p .
46–51, 2007.
[18] A. Yukari, U. Keiko, O. Shigeru, et al., “Clinical assessment
of tacrolimus therapy in lupus nephritis: one-year follow-up




blind multicenter study,” Modern Rheumatology, vol. 19, no. 6,
pp. 606–615, 2009.
[20] H. Bao, Z. H. Liu, H.-L. Xie, W.-X. Hu, H.-T. Zhang, and
L.-S. Li, “Successful treatment of class V+IV lupus nephritis
with multitarget therapy,” Journal of the American Society of
Nephrology, vol. 19, no. 10, pp. 2001–2010, 2008.
[21] H. T. Zhang, W. X. Hu, H. L. Xie, et al., “Randomized
controlled trial of tacrolimus versus intravenous cyclophos-
phamide in the induction therapy of class V plus IV lupus
nephritis,” Nephrology Dialysis Transplantation, vol. 15, pp.
508–514, 2006.
[22] K.S.PetersonandR.Winchester,“Systemiclupuserythemato-
sus,” in Pathogenesis,J .K .W i l l i a ma n dW .M .L a r r y ,E d s . ,p p .
1523–1559, Lippincott Williams & Wilikins, Philadelphia, Pa,
USA, 2005.
[23] K. A. Kirou and M. K. Crow, “New pieces to the SLE cytokine
puzzle,” Clinical Immunology, vol. 91, no. 1, pp. 1–5, 1999.
[24] L. C. Ginus, A. B. Cosim, and P. J. Morris, Transplantation,
Blackwell Science, Oxford, UK, 1999.
[25] S. Sakuma, Y. Kato, F. Nishigaki, et al., “FK506 potently
inhibitsTcellactivationinducedTNF-αandIL-1βproduction
in vitro by human peripheral blood mononuclear cells,”
BritishJournalofPharmacology,vol.130,no.7,pp.1655–1663,
2000.
[26] S. Sakuma, Y. Higashi, N. Sato, et al., “Tacrolimus suppressed
the production of cytokines involved in atopic dermatitis by
directstimulationofhumanPBMCsystem.(Comparisonwith
steroids),” International Immunopharmacology, vol. 1, no. 6,
pp. 1219–1226, 2001.
[27] K. Magari, S. Miyata, F. Nishigaki, Y. Ohkubo, S. Mutoh,
and T. Goto, “Diﬀerential eﬀects of FK506 and methotrexate
on inﬂammatory cytokine levels in rat adjuvant-induced
arthritis,” Journal of Rheumatology, vol. 30, no. 10, pp. 2193–
2200, 2003.
[28] S. Sakuma, Y. Kato, F. Nishigaki, et al., “Eﬀects of FK506
and other immunosuppressive anti-rheumatic agents on T
cell activation mediated IL-6 and IgM production in vitro,”
InternationalImmunopharmacology,vol.1,no.4,pp.749–757,
2001.
[29] Y. Furukawa, H. Yoshikawa, K. Iwasa, and M. Yamada,
“Clinical eﬃcacy and cytokine network-modulating eﬀects of
tacrolimus in myasthenia gravis,” Journal of Neuroimmunol-
ogy, vol. 195, no. 1-2, pp. 108–115, 2008.
[30] M. Sugiyama, M. Funauchi, T. Yamagata, et al., “Predominant
inhibition of Th1 cytokines in New Zealand black/white F1
mice treated with FK506,” Scandinavian Journal of Rheuma-
tology, vol. 33, no. 2, pp. 108–114, 2004.
[31] H. Jiang, C. Wynn, F. Pan, A. Ebbs, L. M. Erickson, and
M. Kobayashi, “Tacrolimus and cyclosporine diﬀer in their
capacity to overcome ongoing allograft rejection as a result
of their diﬀerential abilities to inhibit interleukin-10 produc-
tion,” Transplantation, vol. 73, no. 11, pp. 1808–1817, 2002.
[32] L. Llorente and Y. Richaud-Patin, “The role of interleukin-10
in systemic lupus erythematosus,” Journal of Autoimmunity,
vol. 20, no. 4, pp. 287–289, 2003.
[33] S.Heidt,D.L.Roelen,C.Eijsink,etal.,“Calcineurininhibitors
aﬀect B cell antibody responses indirectly by interfering with
T cell help,” The Journal of Translational Immunology, vol. 159,
no. 2, pp. 199–207, 2009.
[34] P. Blanco, V. Pitard, J.-F. Viallard, J.-L. Taupin, J.-L. Pellegrin,
and J.-F. Moreau, “Increase in activated CD8+ Tl y m p h o c y t e s
expressing perforin and granzyme B correlates with disease
activity in patients with systemic lupus erythematosus,”
Arthritis and Rheumatism, vol. 52, no. 1, pp. 201–211, 2005.
[35] L. Couzi, P. Merville, C. Deminiere, et al., “Predominance
of CD8+ T lymphocytes among periglomerular inﬁltrating
cells and link to the prognosis of class III and class IV lupus
nephritis,” Arthritis and Rheumatism, vol. 56, no. 7, pp. 2362–
2370, 2007.
[36] R.J.Glassock, “Multitarget therapyof lupusnephritis:base hit
or home run?” Journal of the American Society of Nephrology,
vol. 19, no. 10, pp. 1842–1844, 2008.
[37] O. Millan, M. Brunet, J. M. Campistol, et al., “Pharma-
codynamic approach to immunosuppressive therapies using
calcineurin inhibitors and mycophenolate mofetil,” Clinical
Chemistry, vol. 49, no. 11, pp. 1891–1899, 2003.